Timeline Shifts for Ribon's PARP14 Inhibitor: Atopic Dermatitis

Frontiers Ocular Adverse Effects in Atopic Dermatitis Patients Treated With Dupilumab: A Bibliometric Analysis

Timeline Shifts for Ribon's PARP14 Inhibitor: Atopic Dermatitis Phase 1 Trial Extended

Targeting TBK1 to overcome resistance to cancer immunotherapy

Accelerating Biotech Innovation with AI-Powered Early Risk Detection and Clinical Intelligence

PARP14 Inhibitor Program – Ribon Therapeutics

PARP14 is a PARP with both ADP-ribosyl transferase and hydrolase activities

Timeline Shifts for Ribon's PARP14 Inhibitor: Atopic Dermatitis Phase 1 Trial Extended

Revolutionizing Atopic Dermatitis, 11–13 December 2021 - 2022 - British Journal of Dermatology - Wiley Online Library

Optimizing emollient therapy for skin barrier repair in atopic dermatitis - Annals of Allergy, Asthma & Immunology

Novo Nordisk Launches Diabetes Trial in Late-Stage Journey for Semaglutide

Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy

The evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective - David - 2023 - Clinical & Experimental Allergy - Wiley Online Library